2020

Niets magisch aan medicijnprijzen

Nothing magical about medicine prices

US puts pressure on the Netherlands over compulsory licenses

A busy week at the Court of Justice of the European Union

2019

How to measure change in EU Policy

Health Technology Assessments: will 2020 end the deadlock?

Is clinical trial transparency under threat?

REBRAND: Fact or Fiction publication

An insightful day at the EURIPID stakeholder meeting in Budapest

A Momentous Week for Access to Medicines

Dr Marg Ewen Receives the Helen Clark-JoPPP Award

No Universal Health Coverage without Universal Medicines Coverage

2018

A Year at the Heart of Regulatory Decision Making

Staff Spotlight: Jaume Vidal

Time for a Treaty? ReAct Reports on Second Consultation on Global Development & Stewardship Framework to Combat AMR

Medicijnen: de link met de maatschappij

What Role Can Civil Society Play in the European Regulatory Process?

Open Science for Health: Shaping the New Framework Programme

2017

EU-Mercosur Trade Agreement: A bad deal for transparency, policy coherence and access to medicines

New Dutch Government Must Ensure Transparency to Control Medicine Prices

Staff Spotlight: Tim Reed

European Commission Appoints Health Action International to HTA Network Stakeholder Pool

2016

Clinical Trial Data Transparency on Trial – EMA Under Pressure From Pharma Lawsuit

Next Gen Advocates Excel at HAI/HP4L Summer School on Access to Medicines

Farewell to Access to Medicines Pioneer, Andrew Herxheimer

2015

HAI/WHO Pharmaceutical Promotion Manual Still Key to Combating Promotion around the World

HAI Holds Workshops on EU Medicines Policy & Access to Medicines in Eastern Europe

HAI urges MEPs to support key amendments to TTIP resolution

The EU-US Trade Deal Could Leave Europeans Sick

2014

More work needed on new EMA conflicts of interest policy